The role of RBM10 deficiency in limiting tumor cell apoptosis during this early period of initial therapy is distinct from mechanisms that promote the subsequent emergence of acquired resistance after an initial robust tumor response, such as EGFR T790M or MET kinase amplification, which often drives tumor cell proliferation (8–13). Here, MET is linked to neoplasm.